President Donald Trump said that weapons for Taiwan have not yet been approved and will be discussed during a summit with Chinese President Xi Jinping [1, 2].
The timing of these approvals is critical as the U.S. balances its strategic support for Taiwan with the diplomatic complexities of its relationship with China. Any decision on arms sales could significantly alter the security dynamic in the region, potentially escalating tensions or serving as a bargaining chip during bilateral negotiations.
Trump said, "We haven't approved any weapons for Taiwan yet" [1]. He said he will discuss U.S. arms sales to Taiwan with Xi at the summit [2]. The discussions are expected to take place in China, where the two leaders will address U.S. policy on Taiwan and potential weapons transfers [2, 3].
Reports indicate that the summit occurred in March 2026 [3]. According to sources, new weapons for Taiwan could be approved following the conclusion of the trip to China [3]. This sequence suggests that the administration may be using the pending approvals as a point of leverage in high-level talks with the Chinese government.
The U.S. has historically maintained a complex policy of supporting Taiwan's self-defense while officially recognizing the People's Republic of China. The current uncertainty regarding these specific weapon approvals highlights the administration's approach to managing this delicate geopolitical balance, prioritizing direct summit diplomacy before finalizing military commitments.
“"We haven't approved any weapons for Taiwan yet."”
By linking the approval of Taiwanese weaponry to a summit with President Xi, the Trump administration is signaling a transactional approach to regional security. This strategy suggests that military aid to Taiwan is being treated as a negotiable asset rather than a predetermined policy, which may either stabilize relations through compromise or create volatility in Taiwan's defense planning.
